Trial · NCT05986162
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment Emergent Adverse Events | Study Week 20 | Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
| Secondary | Maximum serum concentration of Itolizumab, Cmax | Study Week 16 | Maximum serum concentration of Itolizumab |
| Secondary | Minimum serum concentration of Itolizumab, Cmin | Study Week 16 | Minimum serum concentration of Itolizumab |
| Secondary | Time to maximum serum concentration of Itolizumab, Tmax | Study Week 16 | Time to maximum serum concentration of Itolizumab |
| Secondary | Total Itolizumab exposure across time, AUC0-t | Study Week 16 | Total Itolizumab exposure across time |
| Secondary | Half life of Itolizumab, t1/2 | Study Week 16 | Half life of Itolizumab |
| Secondary | IL-2 | Study Week 16 | Inflammatory Markers：IL-2 |
| Secondary | IL-6 | Study Week 16 | Inflammatory Markers:IL-6 |
| Secondary | TNF-α | Study Week 16 | Inflammatory Markers: TNF-α |
| Secondary | IFN-γ | Study Week 16 | Inflammatory Markers:IFN-γ |
| Secondary | CRP | Study Week 16 | Inflammatory Markers:CRP |
| Secondary | Serum ferritin | Study Week 16 | Inflammatory Markers:Serum ferritin |
| Secondary | ESR | Study Week 16 | Inflammatory Markers:ESR |
| Secondary | IgG | Study Week 16 | Inflammatory Markers：IgG |
| Secondary | IgM | Study Week 16 | Inflammatory Markers：IgM |
| Secondary | IgA | Study Week 16 | Inflammatory Markers： IgA |
| Secondary | CD6 receptor expression levels | Study Week 16 | Mean change of CD6 receptor expression levels in relative to baseline |
| Secondary | T cell subsets | Study Week 16 | Mean change of different proportion of T cell subsets in relative to baseline |
| Secondary | Proportion of patients achieving a TIS of ≥20 | Study Week 16 | Defined as patients with an increase of ≥20 points on the Total Improvement Score in relative to baseline. |
| Secondary | Proportion of patients achieving DOI | Study Week 16 | DOI defined as ≥ 20% improvement in 3 of any 6 core set measures, with no more than 2 core set measures worsening by ≥ 25% (MMT-8 cannot worsen by ≥ 25%). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05986162/registered